Visualization of Human T Lymphocyte-Mediated Eradication of Cancer Cells In Vivo

The authors report a living zebrafish model that allowed the visualization the metastatic cancer cell killing effect by tumor- infiltrating lymphocytes (TILs) and CAR-T cells in vivo at the single-cell level. In a freshly isolated primary human melanoma, specific TILs effectively eliminated metastatic cancer cells in the living body.
[Proceedings of the National Academy of Sciences of the United States of America]
Abstract
Bookmark

No account yet? Register

Share

Alberta Becomes 3rd Province to Offer Promising Leukemia and Lymphoma Treatment

The Province of Alberta and the Alberta Cancer Foundation said that they were teaming up to invest $15 million to offer the leading edge therapy that sees a patient’s own immune cells genetically reprogrammed to attack cancer cells in their body.
Press Release
Bookmark

No account yet? Register

Share

Mitigating the Risk of Cytokine Release Syndrome in a Phase I Trial of CD20/CD3 Bispecific Antibody Mosunetuzumab in NHL: Impact of Translational System Modeling

The authors developed a novel mechanistic model of immune and antitumor responses to the T-cell bispecifics, including the dynamics of B- and T-lymphocytes in circulation, lymphoid tissues, and tumor.
[npj Systems Biology and Applications]
[zotpress userid=’6445212′ items=’7Q3VUWIV’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Increased Lipid Metabolism Impairs NK Cell Function and Mediates Adaptation to the Lymphoma Environment

Scientists found that NK cells in aggressive B cell lymphoma underwent substantial transcriptional reprogramming associated with increased lipid metabolism, including elevated expression of the transcriptional regulator PPAR-g.
[Blood]
[zotpress userid=’6445212′ items=’KCG8HNY6′ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Optimization of Electroporation and other Non‐Viral Gene Delivery Strategies for T Cells

The authors focus on the current state of the most promising non‐viral gene delivery techniques, including electroporation and transfection with cationic polymers or lipids.
[Biotechnology Progress]
[zotpress userid=’1254621′ items=’N6YUT75H’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

New Preclinical Models for Angioimmunoblastic T-cell Lymphoma: Filling the GAP

A complex network of interactions between angioimmunoblastic lymphoma (AITL) tumor cells and the various cells of the tumor microenvironment has impeded the study of AITL pathogenesis in vitro. The authors provide a summary of the pathology, the transcriptional profile and genetic and immune-phenotypic features of human AITL.
[Oncogenesis]
[zotpress userid=’6630899′ items=’XGQ2KSKM’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Different Sites of Extranodal Involvement May Affect the Survival of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma after Chimeric Antigen Receptor T Cell Therapy

The authors found that the different sites of extranodal involvement may affect response, overall survival, and progression-free survival in patients with relapsed or refractory non-Hodgkin lymphoma treated with anti-CD19 CAR-T cells.
[Frontiers of Medicine]
[zotpress userid=’1254621′ items=’Y77EB8IA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

New Preclinical Models for Angioimmunoblastic T-Cell Lymphoma: Filling the GAP

The authors provide a summary of the pathology, the transcriptional profile and genetic and immune-phenotypic features of human angioimmunoblastic lymphoma (AITL). In addition, they give an overview of preclinical models that recapitulate more or less faithfully human AITL characteristics and pathology.
[Oncogenesis]
[zotpress userid=’1254621′ items=’8CIEH8DQ’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma

TG Therapeutics, Inc. announced that the FDA has accepted the company’s New Drug Application for umbralisib, the company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with previously treated marginal zone lymphoma who have received at least one prior anti-CD20 based regimen and follicular lymphoma who have received at least two prior systemic therapies.
[TG Therapeutics, Inc.]
Press Release
Bookmark

No account yet? Register

Share

BryoLogyx Announces Cooperative Research and Development Agreement for Bryostatin-1 with National Cancer Institute

BryoLogyx, Inc. announced that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute, to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia and lymphoma.
[BryoLogyx, Inc.]
Press Release
Bookmark

No account yet? Register

Share

Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Scientists treated 14 relapsed or refractory diffuse large B-cell lymphoma patients by combining autologous hematopoietic stem cell transplantation and anti-CD19 chimeric antigen receptor T-cell therapy.
[Immunotherapy]
[zotpress userid=’1254621′ items=’7W99HMR7′ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share
Share